Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,000 shares of the medical equipment provider's stock, valued at approximately $1,786,000.
Other large investors have also recently added to or reduced their stakes in the company. Van ECK Associates Corp boosted its stake in Boston Scientific by 18.1% in the third quarter. Van ECK Associates Corp now owns 57,894 shares of the medical equipment provider's stock valued at $5,063,000 after acquiring an additional 8,882 shares during the period. Impax Asset Management Group plc boosted its position in Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider's stock valued at $457,138,000 after purchasing an additional 815,403 shares during the period. Concurrent Investment Advisors LLC grew its stake in Boston Scientific by 5.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 9,724 shares of the medical equipment provider's stock worth $815,000 after buying an additional 530 shares during the last quarter. M&G PLC acquired a new stake in Boston Scientific in the third quarter worth $1,327,000. Finally, Capital Performance Advisors LLP bought a new stake in Boston Scientific in the third quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors.
Boston Scientific Stock Performance
Shares of BSX stock traded up $0.90 during trading on Wednesday, reaching $96.42. 8,790,877 shares of the company's stock were exchanged, compared to its average volume of 5,775,970. The firm's fifty day moving average price is $100.66 and its 200-day moving average price is $91.49. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $142.29 billion, a PE ratio of 77.14, a PEG ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a twelve month low of $65.52 and a twelve month high of $107.17.
Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.
Insider Activity
In related news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares in the company, valued at $560,103.60. The trade was a 75.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 137,302 shares of company stock worth $14,319,269. Insiders own 0.50% of the company's stock.
Analysts Set New Price Targets
Several research firms have commented on BSX. Royal Bank of Canada upped their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company increased their price objective on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. TD Cowen lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Friday, January 10th. Finally, UBS Group increased their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $108.91.
Get Our Latest Stock Report on BSX
About Boston Scientific
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
